- Home
- TPB vs SNDX Comparison
TPB vs SNDX Comparison
Compare TPB & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPB
- SNDX
- Stock Information
- Founded
- TPB 1988
- SNDX 2005
- Country
- TPB United States
- SNDX United States
- Employees
- TPB N/A
- SNDX N/A
- Industry
- TPB Tobacco
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- TPB Consumer Discretionary
- SNDX Health Care
- Exchange
- TPB Nasdaq
- SNDX Nasdaq
- Market Cap
- TPB 1.2B
- SNDX 1.1B
- IPO Year
- TPB 2016
- SNDX 2016
- Fundamental
- Price
- TPB $76.33
- SNDX $11.45
- Analyst Decision
- TPB Strong Buy
- SNDX Strong Buy
- Analyst Count
- TPB 4
- SNDX 11
- Target Price
- TPB $73.75
- SNDX $35.91
- AVG Volume (30 Days)
- TPB 206.9K
- SNDX 2.4M
- Earning Date
- TPB 07-31-2025
- SNDX 07-31-2025
- Dividend Yield
- TPB 0.39%
- SNDX N/A
- EPS Growth
- TPB N/A
- SNDX N/A
- EPS
- TPB N/A
- SNDX N/A
- Revenue
- TPB $384,032,000.00
- SNDX $43,722,000.00
- Revenue This Year
- TPB $21.66
- SNDX $426.77
- Revenue Next Year
- TPB $9.08
- SNDX $98.31
- P/E Ratio
- TPB N/A
- SNDX N/A
- Revenue Growth
- TPB 24.54
- SNDX N/A
- 52 Week Low
- TPB $30.62
- SNDX $8.58
- 52 Week High
- TPB $81.05
- SNDX $25.07
- Technical
- Relative Strength Index (RSI)
- TPB 65.15
- SNDX 54.49
- Support Level
- TPB $73.14
- SNDX $10.52
- Resistance Level
- TPB $77.22
- SNDX $11.41
- Average True Range (ATR)
- TPB 1.92
- SNDX 0.66
- MACD
- TPB -0.19
- SNDX 0.22
- Stochastic Oscillator
- TPB 87.01
- SNDX 88.24
About TPB Turning Point Brands Inc.
Turning Point Brands Inc operates as manufacturer, marketer, provider of consumer products that include Other Tobacco Products (OTP) in the U.S. The company offers a wide variety across the OTP spectrum including moist snuff tobacco (MST), loose-leaf chewing tobacco, premium cigarette papers, make- your-own (MYO) cigar wraps, cigars, liquid vapor products, and tobacco vaporizer products. It operates in three segments namely Zig-Zag products; Stoker's products and NewGen products. The company generates maximum revenue from the Zig-Zag products segment.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.